Clinical Trial Update: 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing 18F-FDG and 68Ga-FAPI-46 PET tracers in ER-positive breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 18F-FDG (fluorodeoxyglucose F-18)
• 68Ga-FAPI-46 (Gallium-68-labeled FAPI-46)

Snippet

Sponsor: Maastricht University Medical Center | Conditions: Breast Cancer, Breast Neoplasms | Phase 2 | Status: RECRUITING